Can a change of scenery revive AstraZeneca's stilted R&D?

AstraZeneca ($AZN) is in the midst of transferring its global R&D base to a $500 million campus in Cambridge, U.K., shouldering up with the famed institution in hopes of replicating other companies' successes in biotech hubs and jump-starting its pipeline. As R&D decisionmaker Menelas Pangalos tells The Wall Street Journal, the transition has been difficult, disrupting projects and stretching resources, but the company believes it'll be better suited in a collaborative research environment rather than the remote village that houses its current development operation. More (sub. req.)

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.